Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.


Journal

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703

Informations de publication

Date de publication:
12 2020
Historique:
received: 12 06 2020
revised: 10 09 2020
accepted: 22 09 2020
pubmed: 22 10 2020
medline: 29 9 2021
entrez: 21 10 2020
Statut: ppublish

Résumé

The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward's minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%): median age 75 years, 98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3 (n = 434; 51.6%): median age 72 years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival.

Identifiants

pubmed: 33082079
pii: S1053-2498(20)31758-7
doi: 10.1016/j.healun.2020.09.011
pii:
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1435-1444

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Marius M Hoeper (MM)

Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; German Center of Lung Research (DZL), Hannover, Germany. Electronic address: hoeper.marius@mh-hannover.de.

Christine Pausch (C)

Epidemiological Center, GWT-TUD GmbH, Dresden, Germany.

Ekkehard Grünig (E)

Centre for Pulmonary Hypertension, Thoraxclinic Heidelberg GmbH at Heidelberg University Hospital, Heidelberg, Germany.

Hans Klose (H)

Department of Respiratory Medicine, Eppendorf University Hospital, Hamburg, Germany.

Gerd Staehler (G)

Lungenklinik, Löwenstein, Germany.

Doerte Huscher (D)

Institute of Biometry and Clinical Epidemiology, Charité Universitätsmedizin, Berlin, Germany.

David Pittrow (D)

Epidemiological Center, GWT-TUD GmbH, Dresden, Germany; Medical Faculty, Institute for Clinical Pharmacology, Technical University Dresden, Dresden, Germany.

Karen M Olsson (KM)

Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; German Center of Lung Research (DZL), Hannover, Germany.

Carmine Dario Vizza (CD)

Department of Cardiovascular and Respiratory Diseases, Sapienza, University of Rome, Rome, Italy.

Henning Gall (H)

Department of Internal Medicine, Justus-Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; German Center of Lung Research (DZL), Hannover, Germany.

Nicola Benjamin (N)

Centre for Pulmonary Hypertension, Thoraxclinic Heidelberg GmbH at Heidelberg University Hospital, Heidelberg, Germany.

Oliver Distler (O)

Department of Rheumatology, University Hospital, Zurich, Switzerland.

Christian Opitz (C)

Department of Cardiology, DRK Kliniken Berlin Westend, Berlin, Germany.

J Simon R Gibbs (JSR)

Department of Cardiology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Marion Delcroix (M)

Department of Pneumology, University Hospital Leuven, Leuven, Belgium.

H Ardeschir Ghofrani (HA)

Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany; Department of Internal Medicine, Justus-Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; Department of Medicine, Imperial College, London, London, United Kingdom.

Stephan Rosenkranz (S)

Clinic III for Internal Medicine (Cardiology); Center for Molecular Medicine; Cologne Cardiovascular Research Center (CCRC), University of Cologne, Cologne, Germany.

Ralf Ewert (R)

Department of Respiratory Medicine, Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany.

Harald Kaemmerer (H)

Deutsches Herzzentrum München, Klinik für angeborene Herzfehler und Kinderkardiologie, TU München, Munich, Germany.

Tobias J Lange (TJ)

Department of Internal Medicine II, University Medical Center Regensburg, Regensburg, Germany.

Hans-Joachim Kabitz (HJ)

Gemeinnützige Krankenhausbetriebsgesellschaft Konstanz mbH, Medizinische Klinik II, Konstanz, Germany.

Dirk Skowasch (D)

Innere Medizin - Kardiologie/Pneumologie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Bonn, Germany.

Andris Skride (A)

VSIA Pauls Stradins Clinical University Hospital, Riga Stradinš University, Riga, Latvia.

Elena Jureviciene (E)

Faculty of Medicine of Vilnius University, Referral Centre of Pulmonary Hypertension, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

Egle Paleviciute (E)

Faculty of Medicine of Vilnius University, Referral Centre of Pulmonary Hypertension, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.

Skaidrius Miliauskas (S)

Department of Pulmonology, Pulmonary Hypertension Center, Hospital of Lithuanian University of Health Sciences, Lithuanian University of Health Sciences, Kaunas, Lithuania.

Martin Claussen (M)

Pneumologie, Fachabteilung, LungenClinic Grosshansdorf, Grosshansdorf, Germany.

Juergen Behr (J)

Comprehensive Pneumology Center, Lungenforschungsambulanz, Helmholtz Zentrum, Munich, Germany; Department of Internal Medicine V, Ludwig Maximilians University of Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany; Department of Respiratory Medicine, Asklepios Fachkliniken München-Gauting, Munich, Germany.

Katrin Milger (K)

Department of Internal Medicine V, Ludwig Maximilians University of Munich, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.

Michael Halank (M)

Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden, Germany.

Heinrike Wilkens (H)

Klinik für Innere Medizin, Pneumologie, Universitätsklinikum Universitätskliniken des Saarlandes, Homburg, Germany.

Hubert Wirtz (H)

Abteilung für Pneumologie, Medizinische Klinik und Poliklinik I, Universitätsklinikum Leipzig, Leipzig, Germany.

Elena Pfeuffer-Jovic (E)

Department of Internal Medicine, Respiratory Medicine and Ventilatory Support, Medical Mission Hospital, Central Clinic Würzburg, Würzburg, Germany.

Lars Harbaum (L)

Department of Respiratory Medicine, Eppendorf University Hospital, Hamburg, Germany.

Werner Scholtz (W)

Clinic for General and Interventional Cardiology and Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.

Daniel Dumitrescu (D)

Clinic for General and Interventional Cardiology and Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.

Leonhard Bruch (L)

Klinik für Innere Medizin/Kardiologie, Unfallkrankenhaus Berlin, Berlin, Germany.

Gerry Coghlan (G)

Cardiology, Royal Free Hospital, London, United Kingdom.

Claus Neurohr (C)

Abteilung für Pneumologie und Beatmungsmedizin, Klinik Schillerhöhe, Gerlingen, Germany.

Iraklis Tsangaris (I)

2nd Critical Care Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Matthias Gorenflo (M)

Klinik für Angeborene Herzfehler und Kinderkardiologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Laura Scelsi (L)

Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Anton Vonk-Noordegraaf (A)

Department of Pulmonary Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Silvia Ulrich (S)

Clinic of Pulmonology, University Hospital of Zurich, Zurich, Switzerland.

Matthias Held (M)

Clinic for General and Interventional Cardiology and Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH